VVUS: VIVUS INC. (NASDAQ) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: EyeDrMike who wrote (12014)	7/23/1998 9:27:00 AM
From: AlienTech	Read Replies (5) of 23519

AAO Viagra Study Correction SAN FRANCISCO, July 22 /PRNewswire/ -- The American Academy of Ophthalmology wishes to notify the press of a correction to ''Eye Doctors Caution Viagra Users: Newly Approved Drug May Cause Visual Side Effects,'' released by the Academy on May 1, 1998. One paragraph in the May 1 release refers to a clinical study, reported by the FDA, demonstrating electrical measure of retinal function for study participants dropped by 30 to 50 percent and lasted for at least five hours after taking a high dose of Viagra. This particular study, FDA study 148-232, has been amended by the FDA and the Academy removed this information from our news release. The Academy's amended release can be found on the Academy's website, eyenet.org. For additional information regarding this study, please contact the FDA Center for Drug Evaluation and Research at Tel. 301-594-5329 and reference study 148-232. The mission of the American Academy of Ophthalmology is to achieve accessible, appropriate and affordable eye care for the public by serving the educational and professional needs of the ophthalmologist. SOURCE: American Academy of Ophthalmology

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next